Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 189

1.

Safety and Tolerability of Omalizumab, A Randomized Clinical Trial of Humanized anti-IgE Monoclonal Antibody in Systemic Lupus Erythematosus (STOP LUPUS).

Hasni S, Gupta S, Davis M, Poncio E, Temesgen-Oyelakin Y, Joyal E, Fike A, Manna Z, Auh S, Shi Y, Chan D, Carlucci P, Biehl A, Dema B, Charles N, Balow JE, Waldman M, Siegel RM, Kaplan MJ, Rivera J.

Arthritis Rheumatol. 2018 Dec 29. doi: 10.1002/art.40828. [Epub ahead of print]

PMID:
30597768
2.

Membranous nephropathy: Pilot study of a novel regimen combining cyclosporine and Rituximab.

Waldman M, Beck LH Jr, Braun M, Wilkins K, Balow JE, Austin HA 3rd.

Kidney Int Rep. 2016 Jul;1(2):73-84. Epub 2016 Jun 11.

3.

miR-150 promotes renal fibrosis in lupus nephritis by downregulating SOCS1.

Zhou H, Hasni SA, Perez P, Tandon M, Jang SI, Zheng C, Kopp JB, Austin H 3rd, Balow JE, Alevizos I, Illei GG.

J Am Soc Nephrol. 2013 Jun;24(7):1073-87. doi: 10.1681/ASN.2012080849. Epub 2013 May 30.

4.

Microarray-based gene expression profiling in patients with cryopyrin-associated periodic syndromes defines a disease-related signature and IL-1-responsive transcripts.

Balow JE Jr, Ryan JG, Chae JJ, Booty MG, Bulua A, Stone D, Sun HW, Greene J, Barham B, Goldbach-Mansky R, Kastner DL, Aksentijevich I.

Ann Rheum Dis. 2013 Jun;72(6):1064-70. doi: 10.1136/annrheumdis-2012-202082. Epub 2012 Dec 5.

5.

Glomerular disease: perspectives on maintenance therapy in lupus nephritis.

Balow JE.

Nat Rev Nephrol. 2012 Feb 7;8(3):136-8. doi: 10.1038/nrneph.2012.17. No abstract available.

6.

A decade of mycophenolate mofetil for lupus nephritis: is the glass half-empty or half-full?

Boumpas DT, Bertsias GK, Balow JE.

Ann Rheum Dis. 2010 Dec;69(12):2059-61. doi: 10.1136/ard.2010.139683. No abstract available.

7.

Treatment of type B insulin resistance: a novel approach to reduce insulin receptor autoantibodies.

Malek R, Chong AY, Lupsa BC, Lungu AO, Cochran EK, Soos MA, Semple RK, Balow JE, Gorden P.

J Clin Endocrinol Metab. 2010 Aug;95(8):3641-7. doi: 10.1210/jc.2010-0167. Epub 2010 May 19.

8.

Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study.

Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, Fleisher T, Balow JE, Lipsky PE.

Arthritis Rheum. 2010 Feb;62(2):542-52. doi: 10.1002/art.27221.

9.

Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy.

Austin HA 3rd, Illei GG, Braun MJ, Balow JE.

J Am Soc Nephrol. 2009 Apr;20(4):901-11. doi: 10.1681/ASN.2008060665. Epub 2009 Mar 18.

10.

Chronic granulomatous disease as a risk factor for autoimmune disease.

De Ravin SS, Naumann N, Cowen EW, Friend J, Hilligoss D, Marquesen M, Balow JE, Barron KS, Turner ML, Gallin JI, Malech HL.

J Allergy Clin Immunol. 2008 Dec;122(6):1097-103. doi: 10.1016/j.jaci.2008.07.050. Epub 2008 Sep 26.

11.

Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response index.

Petri M, Kasitanon N, Lee SS, Link K, Magder L, Bae SC, Hanly JG, Isenberg DA, Nived O, Sturfelt G, van Vollenhoven R, Wallace DJ, Alarcón GS, Adu D, Avila-Casado C, Bernatsky SR, Bruce IN, Clarke AE, Contreras G, Fine DM, Gladman DD, Gordon C, Kalunian KC, Madaio MP, Rovin BH, Sanchez-Guerrero J, Steinsson K, Aranow C, Balow JE, Buyon JP, Ginzler EM, Khamashta MA, Urowitz MB, Dooley MA, Merrill JT, Ramsey-Goldman R, Font J, Tumlin J, Stoll T, Zoma A; Systemic Lupus International Collaborating Clinics.

Arthritis Rheum. 2008 Jun;58(6):1784-8. doi: 10.1002/art.23456. Erratum in: Arthritis Rheum. 2008 Sep;58(9):2823.

12.

Systemic lupus international collaborating clinics renal activity/response exercise: comparison of agreement in rating renal response.

Petri M, Kasitanon N, Singh S, Link K, Magder L, Bae SC, Hanly JG, Nived O, Sturfelt G, van Vollenhoven R, Wallace DJ, Alarcón GS, Adu D, Avila-Casado C, Bernatsky SR, Bruce IN, Clarke AE, Contreras G, Fine DM, Gladman DD, Gordon C, Kalunian KC, Madaio MP, Rovin BH, Sanchez-Guerrero J, Steinsson K, Aranow C, Balow JE, Buyon JP, Ginzler EM, Khamashta MA, Urowitz MB, Dooley MA, Merrill JT, Ramsey-Goldman R, Font J, Tumlin J, Stoll T, Zoma A; Systemic Lupus International Collaborating Clinics.

Arthritis Rheum. 2008 Jun;58(6):1789-95. doi: 10.1002/art.23802.

13.

Urinary exosomal transcription factors, a new class of biomarkers for renal disease.

Zhou H, Cheruvanky A, Hu X, Matsumoto T, Hiramatsu N, Cho ME, Berger A, Leelahavanichkul A, Doi K, Chawla LS, Illei GG, Kopp JB, Balow JE, Austin HA 3rd, Yuen PS, Star RA.

Kidney Int. 2008 Sep;74(5):613-21. doi: 10.1038/ki.2008.206. Epub 2008 May 28.

14.

Triad of severe abdominal pain, inappropriate antidiuretic hormone secretion, and disseminated varicella-zoster virus infection preceding cutaneous manifestations after hematopoietic stem cell transplantation: utility of PCR for early recognition and therapy.

Rau R, Fitzhugh CD, Baird K, Cortez KJ, Li L, Fischer SH, Cowen EW, Balow JE, Walsh TJ, Cohen JI, Wayne AS.

Pediatr Infect Dis J. 2008 Mar;27(3):265-8. doi: 10.1097/INF.0b013e31815cb239.

PMID:
18277922
15.

Spectrum of renal diseases associated with extreme forms of insulin resistance.

Musso C, Javor E, Cochran E, Balow JE, Gorden P.

Clin J Am Soc Nephrol. 2006 Jul;1(4):616-22. Epub 2006 Apr 26. Review.

16.

Long-term effects of combination treatment with fludarabine and low-dose pulse cyclophosphamide in patients with lupus nephritis.

Illei GG, Yarboro CH, Kuroiwa T, Schlimgen R, Austin HA, Tisdale JF, Chitkara P, Fleisher T, Klippel JH, Balow JE, Boumpas DT.

Rheumatology (Oxford). 2007 Jun;46(6):952-6. Epub 2007 Feb 22.

PMID:
17317716
17.

Nephrotic syndrome: an under-recognised immune-mediated complication of non-myeloablative allogeneic haematopoietic cell transplantation.

Srinivasan R, Balow JE, Sabnis S, Lundqvist A, Igarashi T, Takahashi Y, Austin H, Tisdale J, Barrett J, Geller N, Childs R.

Br J Haematol. 2005 Oct;131(1):74-9.

PMID:
16173966
18.

Nephropathy in the context of HIV infection.

Balow JE.

Kidney Int. 2005 Apr;67(4):1632-3. No abstract available.

19.

Clinical presentation and monitoring of lupus nephritis.

Balow JE.

Lupus. 2005;14(1):25-30. Review.

PMID:
15732284
20.

Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis.

Takada K, Arefayene M, Desta Z, Yarboro CH, Boumpas DT, Balow JE, Flockhart DA, Illei GG.

Arthritis Rheum. 2004 Jul;50(7):2202-10.

21.

Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: baseline characteristics and course during recombinant leptin therapy.

Javor ED, Moran SA, Young JR, Cochran EK, DePaoli AM, Oral EA, Turman MA, Blackett PR, Savage DB, O'Rahilly S, Balow JE, Gorden P.

J Clin Endocrinol Metab. 2004 Jul;89(7):3199-207.

PMID:
15240593
22.

Maintenance therapy for lupus nephritis--something old, something new.

Balow JE, Austin HA 3rd.

N Engl J Med. 2004 Mar 4;350(10):1044-6. No abstract available.

PMID:
14999117
23.

Treatment of proliferative lupus nephritis.

Balow JE, Austin HA 3rd.

Am J Kidney Dis. 2004 Feb;43(2):383-5. No abstract available.

PMID:
14750105
24.

The classification of glomerulonephritis in systemic lupus erythematosus revisited.

Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M.

J Am Soc Nephrol. 2004 Feb;15(2):241-50. Erratum in: J Am Soc Nephrol. 2004 Mar;15(3):835-6.

25.

The classification of glomerulonephritis in systemic lupus erythematosus revisited.

Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M; International Society of Nephrology Working Group on the Classification of Lupus Nephritis; Renal Pathology Society Working Group on the Classification of Lupus Nephritis.

Kidney Int. 2004 Feb;65(2):521-30. Review. Erratum in: Kidney Int. 2004 Mar;65(3):1132.

26.

Transfusion-associated GVHD after fludarabine therapy in a patient with systemic lupus erythematosus.

Leitman SF, Tisdale JF, Bolan CD, Popovsky MA, Klippel JH, Balow JE, Boumpas DT, Illei GG.

Transfusion. 2003 Dec;43(12):1667-71.

PMID:
14641861
27.

Therapy of membranous nephropathy in systemic lupus erythematosus.

Balow JE, Austin HA 3rd.

Semin Nephrol. 2003 Jul;23(4):386-91. Review.

PMID:
12923727
28.

New insights into the immunopathogenesis and treatment of small vessel vasculitis of the kidney.

Langford CA, Balow JE.

Curr Opin Nephrol Hypertens. 2003 May;12(3):267-72. Review.

PMID:
12698064
29.

A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis.

Boumpas DT, Furie R, Manzi S, Illei GG, Wallace DJ, Balow JE, Vaishnaw A; BG9588 Lupus Nephritis Trial Group.

Arthritis Rheum. 2003 Mar;48(3):719-27.

30.

De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases.

Aksentijevich I, Nowak M, Mallah M, Chae JJ, Watford WT, Hofmann SR, Stein L, Russo R, Goldsmith D, Dent P, Rosenberg HF, Austin F, Remmers EF, Balow JE Jr, Rosenzweig S, Komarow H, Shoham NG, Wood G, Jones J, Mangra N, Carrero H, Adams BS, Moore TL, Schikler K, Hoffman H, Lovell DJ, Lipnick R, Barron K, O'Shea JJ, Kastner DL, Goldbach-Mansky R.

Arthritis Rheum. 2002 Dec;46(12):3340-8.

31.

Choosing treatment for proliferative lupus nephritis.

Balow JE.

Arthritis Rheum. 2002 Aug;46(8):1981-3. Review. No abstract available.

32.

Hereditary periodic fever.

Hull KM, Kastner DL, Balow JE.

N Engl J Med. 2002 May 2;346(18):1415-6; author reply 1415-6. No abstract available.

PMID:
11986423
33.

Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies.

Illei GG, Takada K, Parkin D, Austin HA, Crane M, Yarboro CH, Vaughan EM, Kuroiwa T, Danning CL, Pando J, Steinberg AD, Gourley MF, Klippel JH, Balow JE, Boumpas DT.

Arthritis Rheum. 2002 Apr;46(4):995-1002.

PMID:
11953977
34.

Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course.

Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G, Goldfarb L, Brady RO, Balow JE, Austin Iii HA, Kopp JB.

Medicine (Baltimore). 2002 Mar;81(2):122-38. No abstract available.

35.

Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis.

Illei GG, Austin HA, Crane M, Collins L, Gourley MF, Yarboro CH, Vaughan EM, Kuroiwa T, Danning CL, Steinberg AD, Klippel JH, Balow JE, Boumpas DT.

Ann Intern Med. 2001 Aug 21;135(4):248-57.

PMID:
11511139
36.

Enzyme replacement therapy in Fabry disease: a randomized controlled trial.

Schiffmann R, Kopp JB, Austin HA 3rd, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO.

JAMA. 2001 Jun 6;285(21):2743-9.

PMID:
11386930
37.

Increased levothyroxine requirements presenting as "inappropriate" TSH secretion syndrome in a patient with nephrotic syndrome.

Collins MT, Remaley AT, Csako G, Pucino F, Skarulis MC, Balow JE, Sarlis NJ.

J Endocrinol Invest. 2000 Jun;23(6):383-92.

PMID:
10908166
38.

Treatment of lupus nephritis.

Austin HA, Balow JE.

Semin Nephrol. 2000 May;20(3):265-76. Review.

PMID:
10855936
39.

Progress in the treatment of proliferative lupus nephritis.

Balow JE, Austin HA 3rd.

Curr Opin Nephrol Hypertens. 2000 Mar;9(2):107-15. Review.

PMID:
10757214
40.

New prospects for treatment of lupus nephritis.

Balow JE, Boumpas DT, Austin HA 3rd.

Semin Nephrol. 2000 Jan;20(1):32-9. Review.

PMID:
10651216
41.

A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy.

Boumpas DT, Tassiulas IO, Fleisher TA, Vaughan E, Piscitelli S, Kim Y, Pucino F, Balow JE, Austin HA.

Clin Nephrol. 1999 Aug;52(2):67-75.

PMID:
10480216
42.

Natural history and treatment of lupus nephritis.

Austin HA, Balow JE.

Semin Nephrol. 1999 Jan;19(1):2-11. Review.

PMID:
9952276
43.

Outcome criteria for lupus nephritis trials: a critical overview.

Boumpas DT, Balow JE.

Lupus. 1998;7(9):622-9. Review.

PMID:
9884100
44.

Renal biopsy in lupus nephritis.

Grande JP, Balow JE.

Lupus. 1998;7(9):611-7. Review.

PMID:
9884098
45.

Angiotensin I converting enzyme gene polymorphisms in systemic lupus erythematosus: decreased prevalence of DD genotype in African American patients.

Tassiulas IO, Aksentijevich I, Salmon JE, Kim Y, Yarboro CH, Vaughan EM, Davis JC, Scott DL, Austin HA, Klippel JH, Balow JE, Gourley MF, Boumpas DT.

Clin Nephrol. 1998 Jul;50(1):8-13.

PMID:
9710341
46.
47.

Use of cytotoxic agents and cyclosporine in the treatment of autoimmune disease. Part 1: rheumatologic and renal diseases.

Langford CA, Klippel JH, Balow JE, James SP, Sneller MC.

Ann Intern Med. 1998 Jun 15;128(12 Pt 1):1021-8. Review.

PMID:
9625665
48.

Clinical differences between North African and Iraqi Jews with familial Mediterranean fever.

Pras E, Livneh A, Balow JE Jr, Pras E, Kastner DL, Pras M, Langevitz P.

Am J Med Genet. 1998 Jan 13;75(2):216-9.

PMID:
9450890
49.

Sickle cell nephropathy during the postpartum period in a patient with SLE.

Pham PT, Lew SQ, Balow JE.

Am J Kidney Dis. 1997 Dec;30(6):879-83. Review. No abstract available.

PMID:
9398137
50.

A high-resolution genetic map of the familial Mediterranean fever candidate region allows identification of haplotype-sharing among ethnic groups.

Balow JE Jr, Shelton DA, Orsborn A, Mangelsdorf M, Aksentijevich I, Blake T, Sood R, Gardner D, Liu R, Pras E, Levy EN, Centola M, Deng Z, Zaks N, Wood G, Chen X, Richards N, Shohat M, Livneh A, Pras M, Doggett NA, Collins FS, Liu PP, Rotter JI, Kastner DL, et al.

Genomics. 1997 Sep 15;44(3):280-91.

PMID:
9325049

Supplemental Content

Loading ...
Support Center